Replies to post #36684 on Cytodyn Inc (CYDY)

[d0lphint0m]

He has earned every penny, imo.

[trding]

CEO is taking a far larger salary than most would, where others would get more stock

Half of NP's compensation is going towards incentive stock options. Again this compensation method has a tax benefit vs buying stock directly with cash on which you first pay tax, which he is taking full advantage. NP is using this strategy and pushing the limit, because the previous settled lawsuit, which PRO 140 brought to our attention, was about NP getting more stock options than allowed in his contract per year, forcing him to return some.

[The Lawman]

Pourhassan's salary and benefit package is akin to what a top level CEO of a highly profitable company, with a long track record of success, could expect to receive.

I am not aware of any CEO in a fledgling clinical stage biopharma such as Cytodyn that has received anything close to the salary and compensation package Pourahassan has been taking for many years. Most such CEO's take a minimal salary, and receive most of their compensation in the form of options or warrants.

Pourhassan does not have the background or experience to justify the exorbitant salary he has been taking for many years even if the company was profitable. However, to continue to take an exoribitant salary, without purchasing one share of stock, and while the company continues to bleed money, is outrageous.

I have a big stake in Cytodyn, through numerous Paulson raises (without thereafter selling my stock and holding the warrants, most of which have now expired worthless), and truly want the company to succeed. However, as a significant shareholder, I deeply resent so much of my money being paid to a CEO who is clearly undeserving of being compensated so lavishly.

LM